HK Stock Market Move | HAIXI PHARMA (02637) rose over 5% intraday; HX9428 will enter the optimal window for BD negotiation and collaboration to accelerate global Phase 3 development.

HAIXI PHARMA (02637) rose over 5% intraday. As of press time, it was up 4.29% at HK$160.5, with a turnover of HK$10.7353 million. On the news front, HAIXI PHARMA announced in September that the China Phase I clinical study of HX9428 for the treatment of neovascular age-related macular degeneration (nAMD) has completed the 24-week treatment data observation; the China Phase II dose-expansion study is still ongoing and has yielded interim clinical data. Huafu Securities pointed out that with the readout of the domestic Phase 2b head-to-head data against aflibercept, combined with the U.S. Phase 2a optimal dose exploration validating preliminary efficacy and safety in European and American populations, HX9428 will enter the optimal window for BD negotiation and collaboration, and accelerate global Phase 3 development through partners.